Literature DB >> 33572559

Harnessing Extracellular Matrix Biology for Tumor Drug Delivery.

Nithya Subrahmanyam1,2, Hamidreza Ghandehari1,2,3.   

Abstract

The extracellular matrix (ECM) plays an active role in cell life through a tightly controlled reciprocal relationship maintained by several fibrous proteins, enzymes, receptors, and other components. It is also highly involved in cancer progression. Because of its role in cancer etiology, the ECM holds opportunities for cancer therapy on several fronts. There are targets in the tumor-associated ECM at the level of signaling molecules, enzyme expression, protein structure, receptor interactions, and others. In particular, the ECM is implicated in invasiveness of tumors through its signaling interactions with cells. By capitalizing on the biology of the tumor microenvironment and the opportunities it presents for intervention, the ECM has been investigated as a therapeutic target, to facilitate drug delivery, and as a prognostic or diagnostic marker for tumor progression and therapeutic intervention. This review summarizes the tumor ECM biology as it relates to drug delivery with emphasis on design parameters targeting the ECM.

Entities:  

Keywords:  cancer; drug delivery; extracellular matrix; targeting; tumor

Year:  2021        PMID: 33572559      PMCID: PMC7911184          DOI: 10.3390/jpm11020088

Source DB:  PubMed          Journal:  J Pers Med        ISSN: 2075-4426


  131 in total

1.  Hyaluronidase reduces human breast cancer xenografts in SCID mice.

Authors:  Svetlana Shuster; Gregory I Frost; Antonei B Csoka; Bent Formby; Robert Stern
Journal:  Int J Cancer       Date:  2002-11-10       Impact factor: 7.396

2.  Mesalazine, an osteopontin inhibitor: The potential prophylactic and remedial roles in induced liver fibrosis in rats.

Authors:  A Ramadan; Nehal Afifi; Nemat Z Yassin; Rehab F Abdel-Rahman; Sahar S Abd El-Rahman; Hany M Fayed
Journal:  Chem Biol Interact       Date:  2018-05-05       Impact factor: 5.192

3.  Extracellular matrix remodeling in vivo for enhancing tumor-targeting efficiency of nanoparticle drug carriers using the pulsed high intensity focused ultrasound.

Authors:  Sangmin Lee; Hyounkoo Han; Heebeom Koo; Jin Hee Na; Hong Yeol Yoon; Kyung Eun Lee; Hyukjin Lee; Hyuncheol Kim; Ick Chan Kwon; Kwangmeyung Kim
Journal:  J Control Release       Date:  2017-02-28       Impact factor: 9.776

Review 4.  The Extracellular Matrix Modulates the Metastatic Journey.

Authors:  FuiBoon Kai; Allison P Drain; Valerie M Weaver
Journal:  Dev Cell       Date:  2019-05-06       Impact factor: 12.270

5.  Loss of collagenase-2 confers increased skin tumor susceptibility to male mice.

Authors:  Milagros Balbín; Antonio Fueyo; Angus M Tester; Alberto M Pendás; Ana S Pitiot; Aurora Astudillo; Christopher M Overall; Steven D Shapiro; Carlos López-Otín
Journal:  Nat Genet       Date:  2003-09-28       Impact factor: 38.330

6.  High intensity focused ultrasound hyperthermia for enhanced macromolecular delivery.

Authors:  Nick Frazier; Allison Payne; Joshua de Bever; Christopher Dillon; Apoorva Panda; Nithya Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2016-09-27       Impact factor: 9.776

Review 7.  Integrins as Therapeutic Targets: Successes and Cancers.

Authors:  Sabine Raab-Westphal; John F Marshall; Simon L Goodman
Journal:  Cancers (Basel)       Date:  2017-08-23       Impact factor: 6.639

Review 8.  Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.

Authors:  Muhammad Umair Mushtaq; Athanasios Papadas; Adam Pagenkopf; Evan Flietner; Zachary Morrow; Sibgha Gull Chaudhary; Fotis Asimakopoulos
Journal:  J Immunother Cancer       Date:  2018-07-03       Impact factor: 13.751

Review 9.  Osteopontin as a biomarker for osteosarcoma therapy and prognosis.

Authors:  Xingwen Han; Wenji Wang; Jingjing He; Lei Jiang; Xun Li
Journal:  Oncol Lett       Date:  2019-01-08       Impact factor: 2.967

Review 10.  Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance.

Authors:  Shizhu Chen; Keni Yang; Ruslan G Tuguntaev; Anbu Mozhi; Jinchao Zhang; Paul C Wang; Xing-Jie Liang
Journal:  Nanomedicine       Date:  2015-12-17       Impact factor: 5.307

View more
  2 in total

Review 1.  The 35th Anniversary of the Discovery of EPR Effect: A New Wave of Nanomedicines for Tumor-Targeted Drug Delivery-Personal Remarks and Future Prospects.

Authors:  Hiroshi Maeda
Journal:  J Pers Med       Date:  2021-03-22

2.  EPR Effect-Based Tumor Targeted Nanomedicine: A Promising Approach for Controlling Cancer.

Authors:  Jun Fang
Journal:  J Pers Med       Date:  2022-01-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.